Malignant ovarian germ cell tumors: Identification of novel prognostic markers and long-term outcome after multimodality treatment

Journal of Clinical Oncology

Volumn 24, Issue 30, 2006, Pages 4862-4866

  Murugaesu, Nirupa ^a   Schmid, Peter ^a   Dancey, Gairin ^a   Agarwal, Roshan ^a   Holden, Lydia ^a   McNeish, Iain ^a   Savage, Philip M ^a   Newlands, Edward S ^a   Rustin, Gordon J S ^a   Seckl, Michael J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; METHOTREXATE; VINCRISTINE; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GERM CELL TUMOR; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALIGNANT OVARIAN GERM CELL TUMOR; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVARY CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; BLOOD; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; CHILD; CHILD, PRESCHOOL; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33750617526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.2489     Document Type: Article

References (20)

1. Quirk JT, Natarajan N: Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 97:519-523, 2005
2. Norris HJ, Jensen RD: Relative frequency of ovarian neoplasms in children and adolescents. Cancer 30:713-719, 1972
3. Rustin GJ: Managing malignant ovarian germ cell tumours. BMJ 295:869-870, 1987
4. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers: International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
5. Bajorin DF, Bosl GJ: The use of serum tumor markers in the prognosis and treatment of germ cell tumors. Cancer Principles and Practice of Oncology Updates 6:1-11, 1992
6. Mead GM, Stenning SP, Parkinson MC, et al: The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors: Medical Research Council Testicular Tumour Working Party. J Clin Oncol 10:85-94, 1992
7. Bower M, Fife K, Holden L, et al: Chemotherapy for ovarian germ cell tumours. Eur J Cancer 32A:593-597, 1996
8. Serov SF, Scully RE, Robin IH: International Histologic Classification of Tumours: No. 9 - Histological Typing of Ovarian Tumours. Geneva, Switzerland, World Health Organization, 1973
9. Sheperd JH: Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96:889-892, 1989
10. Bower M, Newlands ES, Holden L, et al: Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8:477-483, 1997
11. Pektasides D, Rustin GJ, Newlands ES, et al: Fertility after chemotherapy for ovarian germ cell tumours. Br J Obstet Gynaecol 94:477-479, 1987
12. Gaffan J, Holden L, Newlands E, et al: Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours: A retrospective long-term follow-up study. Br J Cancer 89:1849-1854, 2003
13. Williams S, Blessing JA, Liao SY, et al: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. J Clin Oncol 12:701-706, 1994
14. Skof E, Grasic Kuhar C, Cerar O, et al: Survival and fertility of patients with malignant ovarian germ cell tumours. Eur J Gynaecol Oncol 25:702-706, 2004
15. Zanagnolo V, Sartori E, Galleri G, et al: Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 25:315-320, 2004
16. Lai CH, Chang TC, Hsueh S, et al: Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 96:784-791, 2005
17. Zanetta G, Bonazzi C, Cantu M, et al: Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 19:1015-1020, 2001
18. Billmire D, Vinocur C, Rescorla F, et al: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An Intergroup Study. J Pediatr Surg 39:424-429, 2004
19. Dark GG, Bower M, Newlands ES, et al: Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15:620-624, 1997
20. Motzer RJ, Sheinfeld J, Mazumdar M, et al: Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18:2413-2418, 2000